Influence of Beta Blockers on Prognosis in Patients With... | NCT04485988

Studies
Influence of Beta Blockers on Prognosis in Patients With Acute Myocardial Infarction Complicated With Normal Ejection Fraction

NCT04485988

Sponsor

Chongqing Medical University

Status

Unknown status

Last Update Posted

Jun 24, 2021Actual

Enrollment

3,000Estimated

Phase

Not provided

Conditions

Interventions

Beta blocker

Countries

China

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Jun 2021

Overall Recruitment Status or Expanded Access Status

Unknown status

Last Known Status

Recruiting

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Jul 1, 2015Actual

Primary Completion Date

Dec 2020Actual

Completion Date

Jul 2021Estimated

First Submitted Date

Jul 22, 2020

First Submission Date that Met QC Criteria

Jul 22, 2020

First Posted Date

Jul 24, 2020Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jun 22, 2021

Last Update Posted Date

Jun 24, 2021Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Not provided

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

To understand the effect of beta blockers on the prognosis of patients with acute myocardial infarction with preserved ejection fraction.

Detailed Description

The use of beta blockers is an important component of drug therapy for myocardial infarction, but in some exceptional cases, evidence-based evidence for their use is insufficient, and we seek to understand the prognostic impact of beta blockers on patients enrolled in long-term follow-up.

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

3,000Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
No-beta blocker
beta blocker			Drug: Beta blocker

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Beta blocker	Drug	Duration of medication	beta blocker

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Death	all-cause mortality	The median time of 3 years

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Patients with acute myocardial infarction

Exclusion Criteria:

Previous history of heart failure admission Killip class > I class cancer pregnant

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

100 Years

Standard Ages

AdultOlder Adult

Study Population

The enrolled patients were from the First Affiliated Hospital of Chongqing Medical University, and the patient information was obtained from the medical record system

Sampling Method

Probability Sample

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
dongying zhang, doctor	Contact	86.27.8901.1596		zhangdongying@cqmu.edu.cn

Overall Officials

Name	Affiliation	Role
dongying zhang, doctor	First Affiliated Hospital of Chongqing Medical University	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
The First Affiliated Hospital of Chongqing Medical University	Recruiting	Chongqing	Chongqing Municipality	400016	China

Intervention Browse Module

MeSH Terms

ID	Term
D000319	Adrenergic beta-Antagonists

Ancestor Terms

ID	Term
D018674	Adrenergic Antagonists
D018663	Adrenergic Agents
D018377	Neurotransmitter Agents
D045504	Molecular Mechanisms of Pharmacological Action

Browse Leaves

Not provided

Browse Branches

Not provided